A blood-count difference is not a direct measurement of brain inflammation. In a small historical human study, people with methamphetamine-use histories had lower hemoglobin and serum L-tryptophan, along with poorer performance on several cognitive measures, than comparison participants. Those findings support further investigation. They do not establish that a blood panel diagnoses methamphetamine-related brain injury or identifies the cause of an individual’s cognitive difficulty.
The distinction matters because the paper discusses a plausible blood–brain mechanism in much stronger detail than its human measurements can directly test. The proposed mechanism and the observed results should remain separate.
Who was studied, and when were the measurements taken?
Chaidee and colleagues published the study in 2023 in the American Journal of Neurodegenerative Disease. It compared 15 patients recruited from a Thai drug-treatment unit with 15 healthy comparison participants. Although the authors describe it as retrospective, the reported analysis is an observational comparison between existing groups, not a randomized drug-administration experiment.
The methamphetamine group reported an average use duration of 11.80 ± 6.11 years and an average abstinence duration of 12.13 ± 1.85 days. These values are means ± standard deviations. The table also reports prior use of 0.30 ± 0.57 g/day. That is historical use information, not a verified administered dose, chemically established product purity, or a measured blood concentration. The study did not supply a controlled route-and-dose exposure series.
There were eight men and seven women in the comparison group, versus six men and nine women in the methamphetamine group. The independent sample consisted of 30 people. Repeated task trials and multiple laboratory endpoints do not increase that participant denominator.
Which specimens and analytes were actually examined?
The investigators collected approximately 3 mL of venous whole blood into an EDTA tube for a complete blood count. This component assessed blood cells and indices such as hemoglobin, hematocrit and mean corpuscular hemoglobin concentration.
The cytokine and L-tryptophan measurements used serum. Blood was allowed to clot, centrifuged, and the separated serum was stored at −80°C until examination. IL-6 and IL-18 were measured by immunoassay, while the tryptophan work used liquid chromatography coupled with mass spectrometry. Whole-blood cell indices and serum molecular measurements are different types of results from different specimen preparations.
Neither preparation was a brain-tissue or cerebrospinal-fluid sample. The study did not directly measure microglial activation, neuronal loss, or a brain concentration of methamphetamine.
What did the blood count show?
| Measurement | Comparison group | Methamphetamine group | Reported comparison |
|---|---|---|---|
| Hemoglobin, g/dL | 13.71 ± 1.77 | 11.38 ± 1.37 | p = 0.0004 |
| Hematocrit, % | 40.90 ± 4.73 | 35.99 ± 4.52 | p = 0.007 |
| Mean corpuscular hemoglobin concentration, g/dL | 33.67 ± 0.97 | 31.67 ± 0.83 | p ≤ 0.0001 |
White-cell numbers and the basophil percentage were also significantly higher in the methamphetamine group. However, the red-cell count, mean corpuscular volume and mean corpuscular hemoglobin were not marked as significantly different in the results table. It would therefore be inaccurate to say that every red-cell measurement declined significantly.
The authors interpreted the overall pattern as potentially consistent with anemia of inflammation. Their interpretation is a proposed explanation, rather than proof that inflammation caused each participant’s lower hemoglobin. A group comparison does not exclude other explanations for a blood-count abnormality or establish an individual diagnosis.
Were both inflammatory cytokines elevated?
No. The results describe serum IL-6 as slightly increased and IL-18 as slightly decreased in the methamphetamine group. They report a significant reduction in L-tryptophan, with p ≤ 0.0001, but do not establish significant group differences for the two cytokines in the corresponding results description. The paper’s figure caption also labels panel A “IL-16,” whereas its assay methods, results heading and discussion identify IL-6. That internal labeling inconsistency should not be silently converted into a separately measured cytokine.
A summary claiming that the study demonstrated significant increases in both IL-6 and IL-18 would reverse the reported direction for IL-18 and overstate the statistical findings. Similarly, lower serum L-tryptophan does not directly establish increased brain concentrations of every downstream metabolite.
Did every cognitive measure show a deficit?
No. The methamphetamine group had lower accuracy or more errors on several measures, including one-back working-memory accuracy and No-Go responding. For example, one-back correct responses averaged 57.10 ± 19.95% versus 78.21 ± 15.22% in controls, with p = 0.0029. No-Go correct responses averaged 91.56 ± 7.44% versus 98.67 ± 3.03%, with p ≤ 0.0001.
Other endpoints did not show significant group differences in the table, including Go response time, one-back hit response time and Wisconsin Card Sorting Test perseverative responses. The findings are selective across outcomes. Neither preserved response speed nor a lower accuracy score should be substituted for the entire cognitive profile.
Why is the proposed biological pathway not a validated diagnostic test?
The discussion links inflammatory signaling, iron handling, tryptophan metabolism and cognition. Its schematic explicitly presents a postulated mechanism. This human comparison did not experimentally manipulate that pathway, follow participants from a pre-use baseline, or show that changing a blood marker changed their cognition.
It also did not validate an individual diagnostic cutoff, report an externally tested prediction model, or establish sensitivity and specificity for methamphetamine-related brain injury. Demonstrating two group differences is not the same as proving that one measurement predicts the other in an individual. Many endpoints were compared using a significance threshold of 0.05; the described statistical approach does not provide a reported correction across the entire collection of comparisons.
The small selected sample, observational design and roughly twelve-day abstinence interval further constrain interpretation. The authors themselves identify abstinence as a limitation when interpreting inflammatory findings. This is not evidence about an experimentally controlled acute intoxication episode.
What can be said in an individual forensic review?
The defensible conclusion is that this study observed selected peripheral blood and cognitive differences in two small groups and proposed a mechanism for further testing. It did not establish that a person’s anemia, cytokine result or tryptophan level proves methamphetamine exposure, causation, irreversible brain injury, or driving impairment at a particular time.
Keep the clinical blood findings, cognitive measurements and toxicology evidence distinct. The study supplies neither a drug-concentration threshold nor a method for reconstructing an individual’s dose or last-use time.
Scientific source
Chaidee N, Kraiwattanapirom N, Pannengpetch S, et al. Cognitive impairment and changes of red blood cell components and serum levels of IL-6, IL-18, and L-tryptophan in methamphetamine abusers. American Journal of Neurodegenerative Disease. 2023;12(1):1–15. PMID: 36937109; PMCID: PMC10018000. Verified full-text bibliographic record and article. Historical observational human study.
Leave a Reply